Wednesday , June 29 2022

Samjin Pharmaceuticals is launching AIDS preventative medicine in the United States



[ad_1]

Partner Saim Quest, FDA 1st Prize has been approved … US National Health Organizations support $ 14.2 million

[팍스넷뉴스 최원석 기자]

Samjin Pharmaceutical





Current price
33,050


A day of the front
1,150


Change
-3.36%


Volume
105,909


The previous day
34,200



2019.05.21 15:30 Chapter closes
closure


(Codename: Duo Gel), which is being developed jointly by the company and its partner ImQuest, has launched clinical trials for commercialization in the United States. It is recognized as an innovative treatment to prevent AIDS. Famous universities such as Johns Hopkins University are taking part in clinical trials, and US health authorities as US National Health Organizations (NIH) support clinical costs. .

ImQuest was recently approved by the US Food and Drug Administration (FDA) for the first phase of clinical studies to determine the safety and drug response response after donation. gel duo; to plasma, the vagina tissue, and cervix of the National Health Organizations. The aim is to complete the first stage examination this year.

Duo gel is the first in the world to develop anti-AIDS drugs with contemporary drugs. Duel gel can be used not only for female genitalia but also for the maternal rectum to prevent the AIDS virus. The global market for HIV / AIDS drugs is estimated to be 21 trillion by 2017, and injections and oral drugs are leading the market to prevent the HIV / AIDS epidemic.

It is hoped that the rate of AIDS infection in underdeveloped countries such as Africa, Latin America and Asia will be significantly reduced, and will be supported by US health authorities. US National Health Organizations will support $ 14.2 million for Phase I and Phase II funding for five years starting this year. Imquest received $ 14.2 million and went into Phase 1 seriously. The National Institute for Allergies and Infectious Diseases (NIAID), sponsored by the National Health Institutions, supports the trial and our consortium of Johns Hopkins University, Brown University, Duke University, University of Pittsburgh, Disease Control Centers and Miriam Hospital.

A duo gel is a preventative medicine for HIV / AIDS that combines 'pyrimidindaion'; developed by Samjin Pharmaceutical and 'Tenofovir', a famous virus treatment. In indigenous studies, it was found that pyrimidinedione prevents the transmission of HIV (human immunodeficiency virus), to kill cultures that are infected with HIV, and to cooperate with Tenofovir to prevent the virus. The World Health Organization (WHO) is expected to be certified as a project supported by US National Health Organizations to prevent AIDS. If Duel's gel is certified by the World Health Organization, it can take part in international applications for drugs in underdeveloped countries.

"The FDA DuoGel Clinic focuses on protecting women at risk for the AIDS virus," said Buck Heights, executive director of gel duo development. "Duogel is a very successful AIDS prevention drug. This will be the first step in the development of subsequent products to protect against vaginal virus transmission and rectum."

Meanwhile Samjin Pharmaceutical signed a licensing agreement with InQuest and Duo Gel in 2005 and owns a 1.2 billion share of Inquest. The global copyright is owned by ImQuest, and the domestic license is owned by Samjin Pharmaceutical. The details of the contract, such as revenue distribution, were not disclosed because of confidentiality with the counterparty. In addition to ImQuest and Duo Gel, Samjin Pharmaceutical signed a licensing agreement for the anticancer drug Piperazine in 2006, and Piperazine is in its pre-clinical period.




[ad_2]
Source link